MagSense Technology Animation
. Cancer treatments are most effective, and patient outcomes are improved, when tumors are detected early. Imagion Biosystems is developing the MagSense™…
Comment on US Preventive Services Task Force Recommendation Statement, "Screening for Ovarian Cancer"
This article represents the viewpoint of management. Background The worldwide incidence of ovarian cancer is 12.6 per 100,000 women. In the year 2006, ovarian…
Investor Update — Corporate Presentation Visuals
Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content…
Magnetic Relaxometry for Cancer Detection
In this second segment of Bob Proulx's presentation to investors at the 2016 NobleCon meeting, he answers the question of how magnetic relaxometry might be…
Company Overview Presentation
click image to download pdf file Here are the principal "slide deck" visuals used to introduce Imagion Biosystems to investors prior to the company's initial…
Magnetic Relaxometry at the 2017 AACR Meeting
This year's Annual Meeting of the American Association for Cancer Research was held April 1-5 in Washington, D.C. The theme of this year's meeting was…
Magnetic Relaxometry at AACR 2017
This year's Annual Meeting of the American Association for Cancer Research was held April 1-5 in Washington, D.C. The theme of this year's meeting was…
Earlier Detection Means An Earlier Cure
Data from the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program, charted below, illustrates the critical importance of…